Stroke Risk Calculator

Major Risk Factors for Stroke and Their Relative Impact

Hypertension stands as the single most important modifiable risk factor for both ischemic and hemorrhagic stroke. The relationship is continuous and graded—there's no threshold below which blood pressure stops influencing risk. A systolic BP of 180 mmHg carries nearly four times the stroke risk of 120 mmHg. The mechanism is multifaceted: chronic hypertension damages arterial walls through shear stress, accelerates atherosclerosis in carotid and intracranial arteries, and weakens small penetrating vessels predisposing to lacunar infarcts and intracerebral hemorrhage. Treatment reduces risk by approximately 35-40% regardless of baseline pressure, making BP control the cornerstone of primary stroke prevention.

Atrial fibrillation multiplies stroke risk by five-fold, and AFib-related strokes tend to be more severe and disabling than other stroke subtypes. The irregular rhythm allows blood stasis in the left atrial appendage, where thrombi form over hours to days. When these emboli dislodge, they typically occlude large intracranial vessels (middle cerebral artery, basilar artery), causing extensive infarcts. The CHA₂DS₂-VASc score stratifies AFib patients into risk categories to guide anticoagulation decisions. A score of 2 or higher (or 3+ in women) generally warrants anticoagulation with warfarin, apixaban, rivaroxaban, edoxaban, or dabigatran, reducing stroke risk by 60-70% with a bleeding risk of 2-3% per year.

Diabetes approximately doubles stroke risk through multiple pathways. Chronic hyperglycemia accelerates atherosclerosis via glycation of lipoproteins and endothelial dysfunction. Diabetics have higher prevalence of hypertension, dyslipidemia, and obesity, compounding vascular risk. Small vessel disease is particularly prominent, manifesting as lacunar strokes and white matter disease (leukoaraiosis) that accumulate subclinically. Tight glycemic control (HbA1c <7%) reduces microvascular complications (retinopathy, nephropathy) substantially but shows only modest stroke risk reduction (10-15%). Blood pressure and lipid management in diabetics yield greater stroke prevention benefit than glucose control alone.

Smoking increases stroke risk 2-4 fold in a dose-dependent manner—more pack-years equals higher risk. Nicotine and carbon monoxide promote platelet aggregation, raise fibrinogen levels, and damage endothelium. Smoking accelerates atherosclerotic plaque formation and makes plaques more prone to rupture. The good news: cessation reduces risk rapidly, with stroke risk dropping by 50% within two years and returning to near-baseline after five years of abstinence. This makes smoking cessation one of the highest-yield interventions, particularly in younger patients where smoking contributes disproportionately to stroke before other risk factors accumulate.

Primary Prevention Strategies Based on Risk Stratification

Low-risk individuals (10-year risk <5%) benefit from lifestyle optimization without necessarily requiring pharmacotherapy. Guidelines recommend 150 minutes weekly of moderate-intensity aerobic exercise, a Mediterranean or DASH diet rich in fruits, vegetables, whole grains, and healthy fats, maintaining BMI under 25, limiting sodium to 2300 mg daily (ideally 1500 mg if hypertensive), and limiting alcohol to 1 drink daily for women or 2 for men. These lifestyle measures reduce stroke risk by an estimated 25-30% and confer cardiovascular benefits beyond stroke prevention. Annual blood pressure checks and screening for diabetes every 3 years suffice for monitoring.

Moderate-risk patients (5-10% 10-year risk) warrant consideration of pharmacological intervention if lifestyle modifications don't achieve targets. Blood pressure above 130/80 mmHg justifies antihypertensive therapy; thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers all show equivalent stroke reduction in trials. Statin therapy (atorvastatin 10-20 mg or rosuvastatin 5-10 mg) reduces stroke risk by 20-25% and is recommended if LDL cholesterol exceeds 100 mg/dL or if diabetes is present. Aspirin for primary prevention remains controversial—current guidelines suggest aspirin 81 mg daily only if cardiovascular disease risk is high and bleeding risk is low, as the 10-15% stroke reduction is offset by a similar increase in major bleeding.

High-risk individuals (10-20% 10-year risk) need intensive multifactorial intervention. Target blood pressure below 130/80 mmHg, often requiring two or three antihypertensive agents. High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) aims for LDL below 70 mg/dL. Diabetics should achieve HbA1c below 7% (or 6.5% if achievable without hypoglycemia). Screening for carotid stenosis with carotid ultrasound is reasonable; asymptomatic stenosis of 70-99% may warrant carotid endarterectomy or stenting in select cases, reducing stroke risk from 13% to 2-3% over five years. Echocardiography to assess for atrial fibrillation, valvular disease, or left ventricular hypertrophy guides additional interventions like anticoagulation or heart failure management.

Very high-risk patients (>20% 10-year risk) often have multiple comorbidities requiring comprehensive management by primary care and specialists. Anticoagulation for atrial fibrillation is mandatory unless absolute contraindications exist (active bleeding, prior intracranial hemorrhage, fall risk so severe that subdural hematoma risk exceeds stroke benefit). Intensive BP control targeting 110-120 mmHg systolic may be appropriate if tolerated without orthostatic symptoms. Cardiac imaging may reveal structural abnormalities (patent foramen ovale, atrial myxoma, ventricular thrombus) requiring specific therapies. Genetic counseling and workup for hereditary stroke syndromes (CADASIL, Fabry disease, sickle cell disease) should be considered in patients under 50 with cryptogenic stroke or strong family history. The goal shifts from population-level guidelines to individualized, precision medicine approaches.

Emerging Risk Factors and Advanced Risk Prediction

Traditional risk scores like Framingham capture the majority of stroke risk but miss emerging biomarkers and imaging findings. Lipoprotein(a) [Lp(a)] is a genetically determined LDL-like particle that's independent of lifestyle and highly thrombogenic. Levels above 50 mg/dL double stroke risk and don't respond to statins. PCSK9 inhibitors (alirocumab, evolocumab) and the newer agent inclisiran can lower Lp(a) by 20-30%, though outcomes data specific to stroke are pending. Routine Lp(a) screening isn't yet recommended, but it's reasonable in patients with premature stroke (<55 years) or strong family history despite optimal management of traditional risk factors.

High-sensitivity C-reactive protein (hsCRP) marks chronic inflammation and independently predicts stroke. Levels above 3 mg/L associate with 2-3 fold higher risk even after adjusting for cholesterol and blood pressure. The mechanism likely involves plaque instability and endothelial dysfunction. Statins lower hsCRP substantially, and the JUPITER trial showed benefit of rosuvastatin in patients with elevated hsCRP (>2 mg/L) despite normal LDL cholesterol. Whether treating hsCRP per se prevents stroke or whether it's merely a marker remains debated, but it provides additional risk stratification beyond lipids alone.

Coronary artery calcium (CAC) scoring via CT quantifies atherosclerotic burden. A CAC score above 100 Agatston units reclassifies many "intermediate risk" patients to high risk, justifying statin therapy. CAC correlates with carotid intima-media thickness and prevalence of carotid plaques. Some stroke neurologists advocate carotid plaque imaging (ultrasound or MRA) to detect asymptomatic stenosis in high-risk patients, though benefits of prophylactic carotid intervention in asymptomatic patients with <70% stenosis are unclear. The imaging can motivate lifestyle changes and medication adherence when patients see visual evidence of their atherosclerotic disease.

Genetic risk scores incorporating hundreds of single-nucleotide polymorphisms are entering clinical use. Polygenic risk scores for stroke can identify individuals whose genetic burden places them in the top quintile of risk despite average traditional risk factors. These patients may benefit from earlier, more aggressive intervention. Conversely, someone with high clinical risk but low genetic risk might tolerate less intensive therapy. Pharmacogenomics also guides treatment—CYP2C19 poor metabolizers don't activate clopidogrel effectively and should receive alternative antiplatelet agents. As whole-genome sequencing costs plummet below $1000, personalized stroke prevention based on individual genetic architecture is becoming feasible, though insurance coverage and clinical workflows lag behind the technology.